Evelo Biosciences Secures $45 Million Debt Financing from K2 HealthVenturesJuly 25, 2019
Evelo Biosciences, Inc. (Nasdaq: EVLO), a biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects, today announced that it has entered into a loan and security agreement for up to $45 million with K2 HealthVentures (K2HV), a healthcare investment firm.
“We are pleased to announce this agreement, which increases our financial flexibility as we advance our clinical portfolio of oral biologics in inflammation and oncology,” said Jonathan Poole, chief financial officer of Evelo. “Throughout their investment process and collaboration with us in structuring this transaction, the K2HV team has demonstrated a deep understanding of Evelo and our novel technology platform.”
K2 HealthVentures Launches New Investment Company with Industry-Leading Team and $400 Million Initial Capital CommitmentMay 21, 2019
-- Will seek to advance development and fuel growth of life sciences and healthcare companies with dual goals of profit and purpose --
K2 HealthVentures (K2HV) announced today the launch of a new specialty finance company that will provide long-term debt, equity, and intellectual capital to private and public life sciences and healthcare companies. With substantial initial funding and a permanent capital base, which is expected to grow significantly over time, the firm will initially target investments ranging in size from $10-50 million. A key principle of K2HV’s charter is its commitment to devoting a portion of investment profits to fund underserved and underinvested areas in the healthcare space, both in the US and globally.
FLEXIBLE, PATIENT CAPITAL
A unique capital structure that enables creative and adaptive financing solutions
PARTNERS FOR GROWTH
A collaborative, experienced investment team with diverse backgrounds in healthcare finance and operations
Submit an investment opportunity